Discussion
Approved Treatments
for ANCA Vasculitis
Fasenra
Fasenra (benralizumab) is an approved therapy for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of AAV. It is administered via a single under-the-skin, or subcutaneous, injection once every four weeks.
Nucala
Nucala (mepolizumab) is a treatment approved for adults with EGPA. It is given via three consecutive subcutaneous injections once every four weeks.
Rituximab
Rituximab is an approved medication for adults and children, aged 2 and older, with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two most common AAV types. It is given via into-the-vein, or intravenous, infusions, once weekly for the first four weeks, and less frequently thereafter.
Tavneos
Tavneos (avacopan) is an oral therapy approved for adults with severe GPA and MPA. It is taken as twice-daily capsules in combination with standard background therapy.